Key result
Loading sucrose nonfermenting-related kinase (SNRK) into dissolving microneedles is proposed as a potential localized protein delivery therapy for cardiac repair.
Answers are grounded in this paper and cite their sources.
This commentary proposes the use of dissolving microneedles as a novel, localized delivery system for SNRK to treat atrial fibrosis and promote cardiac repair in nonischemic heart failure.
Dear Editor, In the article by Ramchandran et al.,1 the authors reported an interesting work on the cardiac repairing effects of sucrose nonfermenting- related kinase (SNRK) in nonischemic heart failure. The results indicated that the absence of SNRK in atrial cardiomyocytes led to cardiac fibrosis. Through in vitro and in vivo studies, the authors confirmed that SNRK could suppress the differentiation of cardiac fibroblasts into pro- fibrotic myofibroblasts and reduce atrial fibrosis. Specifically, SNRK inhibited the expression and secretion of transforming growth factor-β1 (TGF-β1) and blocked the activation of the TGF-β1/ Smad signaling pathway to ultimately achieve the aforementioned anti-fibrotic effects. Based on these findings, the SNRK-TGF-β1 axis is proposed as a potential therapeutic target for intervening in atrial fibrosis associated with nonischemic heart failure. We admired the authors’ valuable scientific contribution. It should be noted that in the study by Ramchandran et al.,1 the authors mainly determined the bioactivities of SNRK, which preliminarily demonstrated its potential as a druggable target, but did not delve into further drug design procedures. We completely understood this issue, as drug design may be outside the scope of the article, and the omission did not compromise the scientific value. In this letter, we would like to address some key considerations for exploiting SNRK as a translatable target for cardiac repair. According to the original study, the upregulation of SNRK is beneficial for protecting the atrium and preventing fibrosis; thus, a potential therapy should be developed to activate SNRK expression, rather than deactivate it. SNRK is a protein biomacromolecule, the molecular information of which is presented in Additional Table 1 (source: RCSB Protein Data Bank). A plausible thought of a train is to screen an agonist for SNRK. However, the process of screening drug candidates is rather complicated and costly. Its primary procedures start with the identification of biological targets and the screening of large compound libraries through high-throughput dry experiments, which are conducted to evaluate the affinity and activity of candidate compounds. This is then followed by the implementation of rigorous in vivo assessments using animal models, specifically including pharmacokinetic, safety, and efficacy assessments, which significantly prolong the research timeline and increase resource consumption.2 Overall, the entire drug candidate screening is characterized by long duration and high cost. In addition, an astronomical number of hypothetical molecules makes brute-force screening infeasible.3 Although technological advances such as machine learning and deep learning aid in improving screening, the multi-stage and iterative nature of compound optimization and validation continues to demand substantial investment and effort. Actually, from the standpoint of drug development, it will be much easier to directly deliver SNRK than to discover an agonist of SNRK or its analog targets, provided that the direct delivery of SNRK is feasible. In this context, the task is converted to "how to deliver protein drugs into the cardiac region.” As we are working in the field of drug delivery, we would like to share some ideas with Ramchandran et al.1 and the broad audiences of Regenerative Medicine Reports. Following the task decomposition strategy, aiming to deliver SNRK into the cardiac region means to 1) encapsulate SNRK in a delivery system and 2) use such a system for cardiac delivery. We consider microneedles (MNs) to be a tailored delivery system that meets the above needs. MNs are composed of hundreds of tiny needle tips with a length of 25-1000 μm integrated on a base in an array. They can directionally break through the skin’s stratum corneum barrier, creating hundreds of mechanical microchannels for drug delivery. Moreover, they do not touch the subcutaneous pain-sensing nerves, thus reducing pain. As shown in Figure 1, MNs are broadly categorized into five types.4 Importantly, we believe that compared with other types of MNs, dissolving MNs are particularly suitable for delivering macromolecular drugs such as SNRK. Solid MNs merely create pores for subsequent drug application, while coated MNs suffer from limited drug loading and potential protein denaturation during coating processes. Hollow MNs can cause clogging and require complex formulations, and hydrogel MNs may involve harsh cross-linking conditions that compromise protein integrity. In contrast, dissolving MNs can encapsulate proteins within biodegradable polymers (e.g., polyvinylpyrrolidone), protecting them from degradation and enabling controlled release upon dissolution. For example, insulin-loaded dissolving MNs have demonstrated efficient transdermal delivery with maintained bioactivity, overcoming the limitations of other MNs types.5 Interestingly, some current studies have developed cardiac MNs patches, which can precisely deliver drugs to the myocardial area and achieve effective retention.6 Undoubtedly, this is an advantage compared with traditional drug delivery methods such as oral administration and injection, as these traditional methods often lead to a large amount of drug distribution in non-target sites, which may cause toxic side effects.Figure 1: Types of microneedles (MNs): solid MNs (A), hollow MNs (B), dissolving MNs (C), coated MNs (D), and hydrogel-forming MNs (E). Created with Adobe Illustrator.Taken together, we propose the idea of loading SNRK into dissolving MNs as a potential pharmaceutical formulation for cardiac repair. This can fully increase the concentration of SNRK at the cardiac lesion site while reducing its distribution in non-target sites. This MNs system has the following advantages: 1) It bypasses the stratum corneum, enabling direct delivery of SNRK into systemic circulation with high bioavailability, overcoming limitations of oral or conventional transdermal routes. 2) The polymer matrix (e.g., polyvinyl pyrrolidone or polyvinyl alcohol/sucrose) dissolves in skin interstitial fluid, providing sustained drug release over hours to days, which is critical for prolonged therapeutic effects in cardiac repair.7 3) The painless, self- administered patch design eliminates needle- related anxiety and sharp waste, while minimizing systemic side effects through localized delivery. 4) Water-soluble polymers (e.g., polyvinyl alcohol) protect protein stability during fabrication and storage, ensuring SNRK retains its pharmacological activity post-delivery.7 We are looking forward to its clinical translation. In addition to the direct delivery of SNRK via MNs, gene delivery platforms including adeno-associated virus serotype 9, mRNA lipid nanoparticles, and CRISPR activation systems can also be employed for SNRK delivery.8 MNs with their precise positioning capability can then serve as a complementary approach. They can be applied for example in local pericardial mRNA delivery or perioperative administration during thoracoscopic surgery to achieve sustained endogenous expression of SNRK. However, the limitations of this system must be clearly identified as follows. 1) Micro-needling at the heart requires a thoracotomy. If a thoracotomy is performed solely for drug administration, the risk is too high. Therefore, it is recommended to perform it when the patient has to undergo a thoracotomy anyway. 2) The micro-scale volume of dissolving MNs restricts the number of macromolecular drugs like SNRK that can be loaded into a single patch, potentially requiring multiple patches for a therapeutic cardiac dose. Therefore, it is recommended to include nanformulations to enhance loading efficiency and dose uniformity.9 3) Inconsistent insertion due to skin elasticity or curvature may prevent MNs from reliably reaching the vascularized dermal layer, limiting systemic drug absorption necessary for cardiac effects. Therefore, it is recommended to utilize MNs rollers or adjustable applicators that ensure consistent penetration depth across diverse skin types and body sites.10 To conclude, this commentary proposed a forward-looking strategy for translating SNRK from a promising molecular target into a practical cardiac repair therapy. We have refined the proposal by positioning the SNRK-loaded dissolving MNs as a complementary, localized protein delivery therapy for specific contexts such as perioperative care. By leveraging dissolving MNs technology, SNRK can be delivered non-invasively yet effectively, achieving sustained release and systemic exposure while preserving protein bioactivity. Although challenges such as loading capacity and insertion consistency remain, formulation optimization and applicator innovation offer clear pathways for improvement. This idea links SNRK’s therapeutic potential with delivery innovation, providing a direction for its clinical translation in cardiac repair. Current MNs delivery strategies for SNRK protein require further investigation due to the lack of a rational intracellular delivery mechanism and insufficient dosage and pharmacokinetic data. Nevertheless, we anticipate that future interdisciplinary efforts- spanning biomaterials science, pharmacology, and cardiac regenerative medicine-will accelerate the preclinical validation and eventual clinical adoption of SNRK-loaded MNs systems. We will be thrilled to read future papers on this topic published in Regenerative Medicine Reports. Declaration of AI and AI-assisted technologies in the writing process: The authors declare that no generative AI was used in the preparation of this manuscript. Open access statement: This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0. Additional file Additional Table 1:Molecular information of SNRK (source: RCSB Protein Data Bank).
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) conducted a letter in Nonischemic heart failure and cardiac fibrosis. SNRK embedded dissolving microneedles was evaluated. Loading sucrose nonfermenting-related kinase (SNRK) into dissolving microneedles is proposed as a potential localized protein delivery therapy for cardiac repair.
Synapse has enriched 10 related papers. Consider them for comparative context: